Skip to main content
Equibles
DRMA logo

DRMA · Dermata Therapeutics, Inc. · Metrics

Track DRMA — free

Use DRMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DRMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.11 +0.01 (+0.45%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”
View the 10-Q filed Aug 11, 2026
Market Cap
$4.58M
Shares
4.02M
Volume · Oct 5 14.1K Avg daily vol (3M) 710.93K

DRMA metrics

48 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.11
Market cap
$4.58M

Price action

20 metrics
Price change (1W)
-3.1%
Price change (30D)
-11.6%
Price change (3M)
-17.5%
Price change (6M)
-14.3%
Price change (YTD)
-52.4%
Price change (1Y)
-77.5%
Trailing year
Price change (5Y)
—
52-week high
$5.38
52-week low
$1.08
Change from 52-week high
-79.5%
Change from 52-week low
+2.8%
Annualized volatility
123.4%
Annualized volatility (3M)
88.3%
Beta
1.2
RSI (14D)
39.4
Price vs SMA 50
-11.8%
Price vs SMA 200
-23.4%
Avg volume (3M)
710,932
Relative volume
0.0
Average dollar volume
$874,253

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.3
reciprocal yield 76.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-182.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-11-15

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$8.60M
Net income (TTM)
−$8.37M
Trailing 12 months
Diluted EPS (TTM)
$-3.25
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.34

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+291.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-239.9%
Return on assets
-157.3%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.41M
Total assets
$5.32M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.08M
Capital expenditures (TTM)
—
R&D (TTM)
$1.63M
SG&A (TTM)
$6.97M
Stock compensation (TTM)
$152,367
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
15
13F filer change QoQ
+7
Institutional ownership
3.7%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1853816 CUSIP 249845504 13F (30d) 1 filings 1 filers Visit website Investor relations